Enterprise Value

513.2M

Cash

791.5M

Avg Qtr Burn

-73.53M

Short % of Float

0.00%

Insider Ownership

0.00%

Institutional Own.

9.15%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tremfya (guselkumab) (IL-23) Details
Psoriatic arthritis, Plaque psoriasis

Approved

Quarterly sales

Monjuvi (Tafasitamab) (CD19) Details
Non-Hodgkin lymphoma, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Diffuse large B cell lymphoma

Approved

Quarterly sales

Tafasitamab (CD19) Details
Cancer, B-cell malignancies, B-cell lymphoma, Diffuse large B cell lymphoma

Phase 3

Data readout

Tafasitamab (CD19) Details
Cancer, B-cell malignancies, Marginal zone lymphoma, Follicular lymphoma

Phase 3

Data readout

Phase 3

Data readout

Gantenerumab Details
Alzheimer's disease

Phase 3

Update

Phase 2

Update